Table 3.
Characterization of NK cell ligands on gastric tumor cells
| Patient 1 (N = 2) | Patient 2 (N = 3) | |||
|---|---|---|---|---|
| Mean | Range | Mean | Range | |
| Inhibitory ligands | ||||
| HLA class 1 | 75% | 71%-80% | 67% | 30%-97% |
| HLA-E | 1% | 0%-1% | 2% | 1%-3% |
| HLA-G | 42% | 28%-56% | 57% | 30%-82% |
| Activating ligands | ||||
| PVR | 8% | 3%-14% | 9% | 3%-18% |
| Nectin-2 | 92% | 87%-98% | 92% | 87%-97% |
| MIC A/B | 2% | 1%-2% | 1% | 0%-1% |
| ULBP-1 | 3% | 2%-4% | 3% | 2%-4% |
| ULBP-2 | 62% | 60%-65% | 67% | 51%-76% |
| ULBP-3 | 3% | 3%-4% | 3% | 2%-4% |
| Other | ||||
| Fas | 36% | 21%-50% | 95% | 88%-99% |
| EGFR | 95% | 93%-98% | 18% | 7%-29% |